We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Events

26 Oct 2026 - 29 Oct 2026
16 Nov 2026 - 19 Nov 2026

Tumor-Initiating Cell Probe makes it Possible to Simultaneously Diagnose and Treat Cancer

By HospiMedica International staff writers
Posted on 05 Apr 2023

Effective prevention measures and timely diagnosis, followed by prompt intervention through effective treatment are crucial in managing cancer. More...

However, the feasibility of providing prompt treatment upon diagnosis remains questionable. Now, researchers have successfully determined the ability of fluorescent probe for tumor-initiating cell yellow (TiY) to stain the cells responsible for tumor growth as well as suppress the growth of those cells at the same time. This promising development offers a single-step solution to both diagnose and treat cancer. Current cancer treatments often fail to completely remove tumors due to metastasis or recurrence, but TiY presents a hopeful approach to overcoming this challenge.

In their previous study, the research team at Pohang University of Science and Technology (POSTECH, Gyeongbuk. Korea), had developed a fluorescent probe called TiY that could selectively identify and detect tumor-initiating cells (TICs), similar to a fluorescent highlighter. Expanding on this achievement, the team conducted further research to investigate TiY's potential for cancer treatment. In the current study, the team examined changes in cancer stem cells in response to varying concentrations of TiY. The team obtained cancer stem cells from patients with lung cancer and transplanted them into mice for experimental purposes. To assess the therapeutic effects of TiY staining, the team gradually increased the dosage of TiY administered to the mice via intravenous injection during their experiments.

The researchers found that at low concentrations, TiY could stain cancer stem cells, but at higher concentrations, it demonstrated an impressive ability to inhibit their growth, resulting in significant destruction of the cancer stem cells. This targeted treatment is facilitated by TiY's unique mechanism, which enables its molecules to selectively bind to vimentin, a muscle-specific protein found in the cytoskeleton of cancer stem cells, thereby enabling TiY to specifically target and suppress these cells.

Related Links:
POSTECH
A*STAR


Gold Member
Blood Gas Analyzer
i-Check200
Hand-held Hemoglobin Analyzer
DiaSpect Tm
Radiofrequency Generator
GX1
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Half-matched bone marrow transplant expands access to curative treatment for children and young adults with severe aplastic anemia. (Photo courtes of Margarita Dionysiou using Bio Render)

Half-Matched Family Donors Could Expand Transplant Access for Severe Aplastic Anemia

Severe aplastic anemia is a rare, life-threatening disorder in which the bone marrow fails to produce enough healthy blood cells, leaving children and young adults vulnerable to anemia, infection, and bleeding.... Read more

Patient Care

view channel
Image: Researchers evaluated the Omni 128 cm long-axial field-of-view PET/CT system, which captures more of the body and radiotracer signal at once, potentially enabling shorter scans. (Photo courtesy of GE HealthCare)

Total-Body PET/CT Scanner Enables One-Minute Diagnostic-Quality Cancer Imaging

Positron emission tomography/computed tomography (PET/CT) combines radiotracer-based functional imaging with anatomical detail to diagnose, stage, and monitor cancer. Conventional scanners image the body... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: Steris is expanding its healthcare consumables portfolio through an agreement to acquire Xodus Medical, a surgical products business focused on patient and operating room staff safety.

Steris to Expand Surgical Safety Portfolio With $2.1 Billion Xodus Medical Deal

Steris has signed a definitive agreement to acquire Xodus Medical, a specialty surgical products business based in Pennsylvania, for $2.1 billion at closing. The acquisition will expand Steris’s healthcare... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.